Published in Int J Gynecol Pathol on January 01, 2003
Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol (2004) 6.20
Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol (2009) 2.94
The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol (2013) 2.47
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol (2009) 1.61
BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol (2010) 1.46
Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. J Oncol (2009) 1.43
A novel immunohistochemical method for estimating cell cycle phase distribution in ovarian serous neoplasms: implications for the histopathological assessment of paraffin-embedded specimens. Br J Cancer (2004) 1.19
Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia (2008) 1.08
Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. Am J Surg Pathol (2009) 0.98
Role of p53 and Rb in ovarian cancer. Adv Exp Med Biol (2008) 0.91
Precursors of endometrial and ovarian carcinoma. Virchows Arch (2009) 0.88
Survival in women with grade 1 serous ovarian carcinoma. Obstet Gynecol (2013) 0.87
Agreement for tumor grade of ovarian carcinoma: analysis of archival tissues from the surveillance, epidemiology, and end results residual tissue repository. Cancer Causes Control (2013) 0.87
Low-grade serous carcinoma of the ovary displaying a macropapillary pattern of invasion. Am J Surg Pathol (2008) 0.83
Serous tumors of the ovary (borderline tumors and carcinomas) with and without micropapillary features. Int J Gynecol Pathol (2003) 0.80
The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer. J Cancer Res Clin Oncol (2010) 0.78
[Serous genital carcinoma: molecular pathogenesis and the role of tubal fimbria]. Pathologe (2009) 0.76
The status of epidermal growth factor receptor in borderline ovarian tumours. Oncotarget (2016) 0.75
KRAS/BRAF Analysis in Ovarian Low-Grade Serous Carcinoma Having Synchronous All Pathological Precursor Regions. Int J Mol Sci (2016) 0.75
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol (2010) 7.27
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol (2004) 6.20
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol (2011) 5.53
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Ovarian cancer. Annu Rev Pathol (2009) 4.92
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol (2009) 3.90
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
The role of chromosomal instability in tumor initiation. Proc Natl Acad Sci U S A (2002) 3.46
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A (2004) 3.35
Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol (2008) 3.22
The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol (2004) 2.95
Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol (2009) 2.94
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol (2005) 2.83
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther (2006) 2.76
p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol (2002) 2.73
ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res (2011) 2.71
Notch3 gene amplification in ovarian cancer. Cancer Res (2006) 2.66
Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol (2010) 2.65
Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol (2008) 2.60
MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One (2008) 2.60
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med (2013) 2.58
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A (2005) 2.29
Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Hum Pathol (2012) 2.27
Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res (2008) 2.26
Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res (2009) 2.25
Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol (2002) 2.18
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst (2012) 2.09
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol (2003) 2.06
Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol (2010) 2.05
Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol (2011) 2.03
Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol (2011) 2.02
Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer (2008) 2.01
TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. J Pathol (2011) 1.94
Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol (2005) 1.94
The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol (2006) 1.91
Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst (2002) 1.90
Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control (2008) 1.89
Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res (2005) 1.80
Identifying tumor origin using a gene expression-based classification map. Cancer Res (2003) 1.78
Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med (2002) 1.72
DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res (2010) 1.71
Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol (2009) 1.71
Amplicon profiles in ovarian serous carcinomas. Int J Cancer (2007) 1.70
The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol (2007) 1.70
Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res (2004) 1.66
Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res (2006) 1.62
Increased plasma DNA integrity in cancer patients. Cancer Res (2003) 1.59
Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol (2011) 1.56
Principle and applications of digital PCR. Expert Rev Mol Diagn (2004) 1.55
Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res (2005) 1.55
A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci U S A (2006) 1.52
Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Am J Surg Pathol (2003) 1.47
The fallopian tube-peritoneal junction: a potential site of carcinogenesis. Int J Gynecol Pathol (2011) 1.47
Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol (2002) 1.46
Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix. Cancer Res (2003) 1.46
Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol (2010) 1.45
Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol (2009) 1.45
Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci (2010) 1.44
Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol (2010) 1.44
Calretinin, a more sensitive but less specific marker than alpha-inhibin for ovarian sex cord-stromal neoplasms: an immunohistochemical study of 215 cases. Am J Surg Pathol (2002) 1.42
Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology (2013) 1.41
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res (2006) 1.41
Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol (2002) 1.40
Ki-67 index as an ancillary tool in the differential diagnosis of proliferative endometrial lesions with secretory change. Int J Gynecol Pathol (2014) 1.39
Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol (2010) 1.39
Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol (2011) 1.37